C4 Therapeutics (CCCC) Twitter Mentions Statistics 2025

10 70.6%

1W 66.7% 1M 47.4%

Est. daily mentions on Twitter.

Similar companies

Company		Twitter Mentions
	Amgen AMGN	24 38.5%
	Gilead Sciences GILD	31 20.5%
	Inovio Pharmaceuticals INO	29 61.1%
	Anavex Life Sciences AVXL	18
	BridgeBio Pharma BBIO	7 61.1%

Month over Month

Est. daily mentions on Twitter.

Aug 2025	213	178.6%
Jul 2025	76	69.7%
Jun 2025	45	118.5%
May 2025	21	26.3%
Apr 2025	28

How often is C4 Therapeutics mentioned on Twitter?

C4 Therapeutics was mentioned an estimated 10 times in various tweets yesterday.

Analyzing Twitter Mentions, how is C4 Therapeutics performing compared to its industry peers?

C4 Therapeutics underperforms its industry peers when it comes to Twitter Mentions, ranking in the 2nd percentile.

Why is it important to track Twitter mentions for C4 Therapeutics?

By monitoring Twitter mentions for C4 Therapeutics, investors gain real-time insights into public sentiment towards the company, its products, and its industry. Positive mentions may indicate growing interest, customer satisfaction, or emerging trends, while negative mentions can alert investors to potential issues, controversies, or market challenges. By tracking these mentions over time, investors can identify patterns, spot emerging trends, and make informed decisions based on the evolving sentiment and public perception of C4 Therapeutics, ultimately improving their investment strategies.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.